ReviewNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology2012
Alzheimer's therapeutics: translation of preclinical science to clinical drug development.
Review in Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Article
- Longitudinal assessment of cognitive function in the APPswe/PS1dE9 mouse model of Alzheimer's-related beta-amyloidosis.Neurobiology of aging · 2023Article
- Combination of Polygoni Multiflori Radix Praeparata and Acori Tatarinowii Rhizoma Alleviates Learning and Memory Impairment in Scopolamine-Treated Mice by Regulating Synaptic-Related Proteins.Frontiers in pharmacology · 2021Article
- Neuroprotective Effects of Quercetin in Alzheimer's Disease.Biomolecules · 2019Review
- Ocular amyloid imaging at the crossroad of Alzheimer's disease and age-related macular degeneration: implications for diagnosis and therapy.Journal of neurology · 2019Review
- Impact of Flavonoids on Cellular and Molecular Mechanisms Underlying Age-Related Cognitive Decline and Neurodegeneration.Current nutrition reports · 2018Review
- Animal tests for anxiety-like and depression-like behavior in rats.Interdisciplinary toxicology · 2017Article
- A Novel Way of Amelioration of Amyloid Beta Induced Toxicity inAnnals of neurosciences · 2016Article
- Misoprostol Reverse Hippocampal Neuron Cyclooxygenase-2 Downstream Signaling Imbalance in Aluminum-Overload Rats.Current Alzheimer research · 2016Article
- Co-immunization with DNA and protein mixture: a safe and efficacious immunotherapeutic strategy for Alzheimer's disease in PDAPP mice.Scientific reports · 2015Article
- Women with the Alzheimer's risk marker ApoE4 lose Aβ-specific CD4⁺ T cells 10-20 years before men.Translational psychiatry · 2014Article
- Building a pipeline to discover and validate novel therapeutic targets and lead compounds for Alzheimer's disease.Biochemical pharmacology · 2014Review
- Quantitative analysis of the flavonoid glycosides and terpene trilactones in the extract of Ginkgo biloba and evaluation of their inhibitory activity towards fibril formation of β-amyloid peptide.Molecules (Basel, Switzerland) · 2014Article
- Meserine, a novel carbamate AChE inhibitor, ameliorates scopolamine-induced dementia and alleviates amyloidogenesis of APP/PS1 transgenic mice.CNS neuroscience & therapeutics · 2014Article
- Structured evaluation of rodent behavioral tests used in drug discovery research.Frontiers in behavioral neuroscience · 2014Review
- Senescence-accelerated OXYS rats: a model of age-related cognitive decline with relevance to abnormalities in Alzheimer disease.Cell cycle (Georgetown, Tex.) · 2014Review
- The battle of Alzheimer's Disease - the beginning of the future Unleashing the potential of academic discoveries.Frontiers in pharmacology · 2014Article
- Article
- Clinical phenotype of dementia after traumatic brain injury.Journal of neurotrauma · 2013Article
- Dementia resulting from traumatic brain injury: what is the pathology?Archives of neurology · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Over the past three decades, significant progress has been made in understanding the neurobiology of Alzheimer's disease. In recent years, the first attempts to implement novel mechanism-based treatments brought rather disappointing results, with low, if any, drug efficacy and significant side effects. A discrepancy between our expectations based on preclinical models and the results of clinical trials calls for a revision of our theoretical views and questions every stage of translation-from how we model the disease to how we run clinical trials. In the following sections, we will use some specific examples of the therapeutics from acetylcholinesterase inhibitors to recent anti-Aβ immunization and γ-secretase inhibition to discuss whether preclinical studies could predict the limitations in efficacy and side effects that we were so disappointed to observe in recent clinical trials. We discuss ways to improve both the predictive validity of mouse models and the translation of knowledge between preclinical and clinical stages of drug development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.